New ulcerative colitis drug enters first human safety trial
NCT ID NCT06681181
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug called GSK4528287 for the first time in humans. The goal is to check for side effects and see how the drug behaves in the body. 48 healthy volunteers will receive a single dose, with the amount increased gradually in different groups. If it's safe, this could lead to future studies in people with ulcerative colitis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GSK4528287
- What this could lead to
- If this drug proves safe, it could lead to a new treatment option for people with inflammatory bowel diseases like ulcerative colitis.
- What could go wrong
- This is a very early, small phase 1 trial in healthy volunteers, not patients. The drug may not work or could have side effects that stop further development.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Cambridge, CB2 0GG, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new biologic tame ulcerative colitis?
- Can a Real-World study reveal the staying power of guselkumab?
- Can a new biologic calm the immune attack in ulcerative colitis?
- Can better detection of precancerous lesions in IBD prevent colorectal cancer?
- Dutch hospital data reveals hidden patterns in IBD treatment
- Kids' metabolism under the microscope: new study on IBD and energy burn